Figure 1.

Incidence of treatment related adverse events in the pivotal study of rituximab in relapsed and refractory indolent non-Hodgkin's lymphoma, stratified by infusion number. From McLaughlin and coworkers [13]. Reprinted with permission from the American Society of Clinical Oncology.

Hainsworth Arthritis Res Ther 2003 5(Suppl 4):S12-S16   doi:10.1186/ar1008